194785-93-8

Upstream product

• 220612-64-6 ((2R,3S,4S,5R,6S)-6-(((1S,2S,3R,4S,6R)-4,6-bis((tert-butoxycarbonyl)amino)-3-(((2R,3R,5S,6R)-3-((tert-butoxycarbonyl)methyl)-5-hydroxytetrahydro-2Hpyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)-4-((tert-butoxycarbonyl)amino)-3,5-dihydroxytetrahydro-2H-pyran-2-yl)methyl 2,4,6-triisopropylbenzenesulfonate 
• 2150-02-9 bis(2-mercaptoethyl)ether 
• 194785-92-7 tosyl-Boc₅-tobramycin 

Downstream Products

• 194785-94-9 C₅₂H₈₈N₆O₁₉S₃ 

Relevant academic research and scientific papers

Cellular uptake of aminoglycosides, guanidinoglycosides, and poly-arginine

Aminoglycosides (including neomycin B and tobramycin) exhibit poor uptake by eukaryotic cell lines. When the amines of these natural products are converted into guanidine groups, their cellular uptake is dramatically enhanced. We have synthesized BODIPY-c

GUANIDINIUM DERIVATIVES FOR IMPROVED CELLULAR TRANSPORT

Reagents and methods useful for the synthesis of conjugates comprising guanidinylated cyclic acetals are provided. Also provided are methods for increasing the cellular uptake of various therapeutic compounds and treatment modalities using these conjugate

Enhanced RNA binding of dimerized aminoglycosides

Aminoglycoside antibiotics have recently emerged as an intriguing family of RNA binding molecules and they became leading structures for the design of novel RNA ligands. The demystification of the aminoglycoside-RNA recognition phenomenon is required for

Dimeric aminoglycosides: Design, synthesis and RNA binding

The design and synthesis of symmetrical and non-symmetrical dimeric aminoglycosides derived from kanamycin A, tobramycin, and neomycin B are described. The covalently-linked dimeric aminoglycosides show enhanced activity as ribozyme inhibitors when compared to their natural counterparts.